As PD-1 inhibitors march toward earlier-stage head and neck cancers, researchers consider ways to improve the precision of immunotherapy through better patient selection and combinations for this accessible tumor type.
With Phase III trials ongoing of leading PD-1/L1 inhibitors in first-line treatment of recurrent or metastatic cancers of the head and neck, new research already is moving the future target to the neoadjuvant setting, prior to surgery and chemoradiation, with curative intent.
Squamous cell carcinomas of the head and neck (SCCHN or HNSCC) include tumors that start in the mouth, nose and...
Aurigene Oncology CEO talks in this audio interview about the tough biotech funding environment, pipeline assets including a CAR-T therapy in Phase II, "hybrid" manufacturing, outcome-based reimbursement and the promise of bispecifics and multispecifics, including Akeso's PD-1/VEGF bispecific.
The company said it will no longer use ALLO-647 after a patient developed a fatal adenovirus infection, and it will pursue further development of its Dagger technology to minimize or eliminate the need for lymphodepletion.
The UK major continues to post promising data readouts that further emphasize the safety and efficacy of its blockbuster lung cancer drug, but competition from J&J's Rybrevant is ramping up, and capable challengers are emerging.
Its multibillion dollar investment demonstrates the importance of the US to AstraZeneca, with half of its targeted $80bn revenues by 2030 set to come from the country, Pascal Soriot said as it presented strong second-quarter results.
The company, with partner Bristol Myers Squibb, has a three-wave development strategy for BNT-327: “establish, combine, broaden.”
The UK major continues to post promising data readouts that further emphasize the safety and efficacy of its blockbuster lung cancer drug, but competition from J&J's Rybrevant is ramping up, and capable challengers are emerging.
Japan has emerged as a global leader in the development of new drugs for the rare cancer angiosarcoma, reflecting its rapidly ageing population and the limitations of current therapies.
